APHP, Avicenne Hospital, Pharmacology Laboratory, Bobigny, France. gerard.perret @ avc.aphp.fr
Minerva Med. 2010 Jun;101(3):163-78.
Metastasis accounts for over 90% of cancer patient deaths. In spite of this , the majority of the currently used drugs are aimed at eradicating or controlling the primary tumor. Hardly any cancer therapies used at the moment interfere only with metastasis and there is a need for drugs acting specifically on the metastatic processes, curing the minimal residual disease and being less toxic than the current drugs. Searching for drugs that do not affect the growth of the primary tumor but inhibit the colonization and/or the outgrowth in distant sites could lead to new drugs specifically aimed at treating the minimal residual disease. The aim of this work is to search at what conditions such drugs might be discovered and if some exist already. For that, mechanisms of actions of current experimental and clinical antimetastatic drugs are described and their utility for different clinical settings (primary prevention, adjuvant setting) is analyzed. In conclusion, clues exist that specific antimetastatic drugs could exist and will be developed in a near future.
转移是超过 90%癌症患者死亡的原因。尽管如此，目前使用的大多数药物都旨在根除或控制原发性肿瘤。目前几乎没有任何癌症治疗方法只针对转移，因此需要专门针对转移过程的药物，既能治愈微小残留疾病，又比现有药物毒性更小。寻找不影响原发性肿瘤生长但能抑制定植和/或远处扩散的药物，可能会开发出专门针对治疗微小残留疾病的新药。这项工作的目的是探讨在什么条件下可能发现这些药物，如果已经存在的话。为此，描述了目前实验性和临床抗转移药物的作用机制，并分析了它们在不同临床环境（初级预防、辅助治疗）中的应用。总之，存在特定抗转移药物可能存在的线索，并将在不久的将来得到开发。
